Alx Historical Income Statement
| ALXO Stock | USD 1.48 0.03 1.99% |
Historical analysis of Alx Oncology income statement accounts such as Net Interest Income of 9.5 M, Depreciation And Amortization of 544.7 K or Interest Expense of 1.2 M can show how well Alx Oncology Holdings performed in making a profits. Evaluating Alx Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Alx Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Alx Oncology Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alx Oncology Holdings is a good buy for the upcoming year.
Alx |
About Alx Income Statement Analysis
Alx Oncology Holdings Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Alx Oncology shareholders. The income statement also shows Alx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Alx Oncology Income Statement Chart
Add Fundamental
Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Alx Oncology Holdings. It is also known as Alx Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Alx Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Alx Oncology Holdings current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, Alx Oncology's Interest Income is very stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 83.6M | 127.4M | 170.3M | 178.8M | Cost Of Revenue | 736K | 1.5M | 836K | 1.4M |
Alx Oncology income statement Correlations
Click cells to compare fundamentals
Alx Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alx Oncology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (21K) | (811K) | (13K) | 4.3M | 9.1M | 9.5M | |
| Depreciation And Amortization | 424K | 202K | 736K | 342K | 836K | 544.7K | |
| Interest Expense | 21K | 811K | 13K | 4.4M | 1.6M | 1.2M | |
| Selling General Administrative | 3.3M | 14.8M | 23.4M | 29.0M | 28.5M | 18.6M | |
| Gross Profit | 436K | 107K | (736K) | (1.5M) | (836K) | (794.2K) | |
| Other Operating Expenses | 24.0M | 44.8M | 83.6M | 127.4M | 170.3M | 85.4M | |
| Operating Income | (19.2M) | (43.7M) | (83.6M) | (127.4M) | (170.3M) | (161.8M) | |
| Net Income From Continuing Ops | (19.2M) | (45.7M) | (83.5M) | (123.5M) | (160.8M) | (152.8M) | |
| Ebit | (19.2M) | (43.7M) | (84.2M) | (127.4M) | (159.2M) | (151.3M) | |
| Research Development | 16.3M | 29.0M | 60.2M | 98.4M | 141.8M | 148.9M | |
| Ebitda | (18.8M) | (43.5M) | (83.5M) | (127.1M) | (158.4M) | (150.5M) | |
| Cost Of Revenue | 4.4M | 1.1M | 736K | 1.5M | 836K | 1.4M | |
| Total Operating Expenses | 19.6M | 43.8M | 83.6M | 127.4M | 170.3M | 178.8M | |
| Reconciled Depreciation | 429K | 202K | 51K | 342K | 836K | 420.0K | |
| Income Before Tax | (19.2M) | (45.5M) | (83.5M) | (123.4M) | (160.8M) | (152.8M) | |
| Total Other Income Expense Net | (26K) | (1.8M) | 71K | 4.0M | 9.5M | 9.9M | |
| Net Income Applicable To Common Shares | (23.3M) | (50.9M) | (83.5M) | (123.5M) | (111.1M) | (105.6M) | |
| Net Income | (19.2M) | (45.7M) | (83.5M) | (123.5M) | (160.8M) | (152.8M) | |
| Income Tax Expense | 34K | 241K | (21K) | 64K | 57.6K | 58.1K |
Pair Trading with Alx Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with Alx Stock
Moving against Alx Stock
| 0.77 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.68 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.62 | VERA | Vera Therapeutics | PairCorr |
| 0.61 | VCYT | Veracyte | PairCorr |
| 0.38 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.97) | Quarterly Revenue Growth (1.00) | Return On Assets (0.49) | Return On Equity (0.99) |
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.